UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunogenicity of biologics in inflammatory bowel disease

Therapeutic advances in gastroenterology, 2018-01, Vol.11, p.1756283X17750355-1756283X17750355

2018

Volltextzugriff (PDF)

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

Journal of clinical pharmacology, 2015-03, Vol.55 (S3), p.S39-S50

2015

Volltextzugriff (PDF)

Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin

Seminars in thrombosis and hemostasis, 2013-06, Vol.39 (4), p.356-364

2013

Volltextzugriff (PDF)

Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing

Alimentary pharmacology & therapeutics, 2018-10, Vol.48 (7), p.731-739

2018

Volltextzugriff (PDF)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Gut, 2015-10, Vol.64 (10), p.1539-1545

2015

Volltextzugriff (PDF)

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

Clinical gastroenterology and hepatology, 2014-09, Vol.12 (9), p.1474-1481.e2

2014

Volltextzugriff (PDF)

Prediction and Reduction of the Aggregation of Monoclonal Antibodies

Journal of molecular biology, 2017-04, Vol.429 (8), p.1244-1261

2017

Volltextzugriff (PDF)

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

Journal of Crohn's and colitis, 2019-07, Vol.13 (7), p.864-872

2019

Volltextzugriff (PDF)

Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor

Analytical chemistry (Washington), 2017-03, Vol.89 (6), p.3664-3671

2017

Volltextzugriff (PDF)

Risk Assessment and Monitoring of Antibody Responses to Biosimilars in Chronic Inflammatory Diseases

Current pharmaceutical design, 2017-01, Vol.23 (44), p.6739-6745

2017

Volltextzugriff (PDF)

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease

The American journal of gastroenterology, 2016-10, Vol.111 (10), p.1438-1445

2016

Volltextzugriff (PDF)

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Thrombosis research, 2012-10, Vol.130 (4), p.576-585

2012

Volltextzugriff (PDF)

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment

Current drug targets, 2018-01, Vol.19 (7), p.757-776

2018

Volltextzugriff (PDF)

Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice

Stroke (1970), 2016-09, Vol.47 (9), p.2419-2422

2016

Volltextzugriff (PDF)

Fatigue in children and adolescents with inflammatory bowel disease

World journal of gastroenterology : WJG, 2019-02, Vol.25 (5), p.632-643

2019

Volltextzugriff (PDF)

Thromboembolism as an important complication of inflammatory bowel disease

European journal of gastroenterology & hepatology, 2016-01, Vol.28 (1), p.1-7

2016

Volltextzugriff (PDF)

Eczematous eruption after guselkumab treatment for psoriasis

JAAD Case Reports, 2019-11, Vol.5 (11), p.973-975

2019

Volltextzugriff (PDF)

Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives

Current gastroenterology reports, 2014-04, Vol.16 (4), p.378, Article 378

2014

Volltextzugriff (PDF)

Recurrent pericarditis as an extra‐intestinal manifestation of ulcerative colitis in a 14‐year‐old girl

Clinical case reports, 2018-08, Vol.6 (8), p.1538-1542

2018

Volltextzugriff (PDF)

Heterobifunctional PEG ligands for bioconjugation reactions on iron oxide nanoparticles

PloS one, 2014-10, Vol.9 (10), p.e109475

2014

Volltextzugriff (PDF)

PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

Nature medicine, 2014-07, Vol.20 (7), p.741-747

2014

Volltextzugriff (PDF)

Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth

Oncogene, 2004-09, Vol.23 (41), p.6986-6990

2004

Volltextzugriff (PDF)

Efficacy and Safety Profile of Anti–Tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn’s Disease: A Network Meta-analysis of Indirect Comparisons

Clinical therapeutics, 2016-06, Vol.38 (6), p.1342-1358.e6

2016

Volltextzugriff (PDF)

Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost

Digestive diseases (Basel), 2017-01, Vol.35 (1-2), p.61-68

Gils, Ann

2017

Volltextzugriff (PDF)

Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms

PloS one, 2017-05, Vol.12 (5), p.e0177117-e0177117

2017

Volltextzugriff (PDF)

1 – 25 von 334

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(319)
Mit Volltextzugriff
(254)

Publikationsform

Sprache

Englisch
(333)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Immunogenicity of biologics in inflammatory bowel disease

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin

Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

Prediction and Reduction of the Aggregation of Monoclonal Antibodies

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor

Risk Assessment and Monitoring of Antibody Responses to Biosimilars in Chronic Inflammatory Diseases

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment

Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice

Fatigue in children and adolescents with inflammatory bowel disease

Thromboembolism as an important complication of inflammatory bowel disease

Eczematous eruption after guselkumab treatment for psoriasis

Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives

Recurrent pericarditis as an extra‐intestinal manifestation of ulcerative colitis in a 14‐year‐old girl

Heterobifunctional PEG ligands for bioconjugation reactions on iron oxide nanoparticles

PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth

Efficacy and Safety Profile of Anti–Tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn’s Disease: A Network Meta-analysis of Indirect Comparisons

Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost

Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms

Suchergebnisse filtern